0807 GMT - AstraZeneca struck an upbeat tone on its prospects through 2030 and beyond, signaling it doesn't need dealmaking to deliver growth into the next decade due to its pipeline, Berenberg analysts say in a research note. Executives at the U.K. drugmaker still expect clinical trials for which the company is due to report results this year to unlock more than $10 billion in combined annual peak sales, according to Berenberg. While its Wainua drug failed in a heart-disease study, higher-than-previously-expected sales potential for its respiratory medicine tozorakimab should make up for the shortfall, the analysts say. AstraZeneca now sees tozorakimab peak sales at more than $5 billion. Shares fall 1.7%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 28, 2026 04:08 ET (08:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.